ArticlePloS one2018

Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy.

Obiageli Offor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.